# Hinova Pharmaceuticals

Source: https://onco.cc/companies/hinova-pharmaceuticals/  
OnCo record `hinova-pharmaceuticals` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Hinova Pharmaceuticals is a China-based biotechnology company running 2 late-stage cancer trials of HP518 - Dose Escalation, HP518 -Dose Expansion and HC-1119 in prostate cancer.

## Summary

Hinova Pharmaceuticals, based in Chengdu, China, is a biotechnology company listed as 688302.SH. Hinova (also known as Haichuang Pharmaceutical) develops innovative drugs in oncology, metabolic disease and autoimmune/inflammatory conditions, using targeted protein degradation, deuterated-drug and translational medicine platforms. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing HP518 - Dose Escalation, HP518 -Dose Expansion and HC-1119 in prostate cancer. The largest, NCT03851640 (A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)), plans to enrol 417 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Hinova Pharmaceuticals Inc.
- Tags: ctgov-sponsor
- HQ: Chengdu
- Type: biotech
- Website: https://www.hinovapharma.com
- Ticker: 688302.SH

## Sources

- Official website: https://www.hinovapharma.com
- ClinicalTrials.gov: trials led by Hinova Pharmaceuticals: https://clinicaltrials.gov/search?lead=Hinova%20Pharmaceuticals%20Inc.

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)
- trials: [A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients](https://onco.cc/trials/nct06155084/), [A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).](https://onco.cc/trials/nct03851640/)

---
JSON: https://onco.cc/api/v1/entities/hinova-pharmaceuticals.json